|Assessment Status||Rapid Review Complete|
|Indication||Is indicated for the treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.|
|Rapid review commissioned||12/12/2022|
|Rapid review completed||25/01/2023|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.